-
12 June 2025 12:51:01
- Source: Sharecast
12 June 2025
ImmuPharma PLC
("ImmuPharma" or the "Company")
2025 RESULT OF ANNUAL GENERAL MEETING
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 - 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details are contained in the table below.
|
Resolution |
For |
% For |
Against |
% Against |
Withheld |
|
1. To receive the accounts of the Company for the year ended 31 December 2024 together with the reports thereon of the directors and auditors of the Company |
88,682,323 |
74 |
30,840,722 |
26 |
74,472 |
|
2. To re-appoint Dr Tim Franklin as a director of the Company |
86,938,536 |
74 |
31,136,460 |
26 |
1,522,521 |
|
3. To re-appoint Tim McCarthy as a director of the Company |
86,900,286 |
73 |
32,579,135 |
27 |
118,096 |
|
4. To re-appoint Crowe UK LLP as Auditor of the Company |
86,901,988 |
76 |
27,981,718 |
24 |
4,713,811 |
|
5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting |
84,856,858 |
71 |
34,558,813 |
29 |
181,846 |
|
SPECIAL RESOLUTION |
84,812,828 |
71 |
34,602,843 |
29 |
181,846 |
As at the date of the AGM, the number of issued ordinary shares of the Company was 499,723,932 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.
Ends
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.